ruxolitinib news

All news on ruxolitinib (also known as Jakafi and Jakavi): plants, production capacities, investments and involved companies.

13 June 2026

Lilly reports Phase 1 results for AJ1-11095, a first‑in‑class type II JAK2 inhibitor

Phase 1 data show 70% SVR35 and TSS50 rates, VAF reductions in 21/23 patients, no dose‑limiting toxicities; expansion and further indications planned.

Who will be producing ruxolitinib in the future?

Find out with chemXplore Alpha

Learn more